Literature DB >> 12845415

Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Tonmoy Sharma1, Catherine Hughes, William Soni, Veena Kumari.   

Abstract

RATIONALE: Schizophrenia patients are known to manifest widespread, multifaceted cognitive deficits. There is now an increasing emphasis on the critical importance of cognitive deficits for the functional outcome in schizophrenia. Typical antipsychotics, although effective in reducing positive symptoms of the illness, have not shown much effect on cognitive functions. Atypical antipsychotics have shown promise of improving some cognitive functions.
OBJECTIVES: This naturalistic study aimed to determine whether olanzapine and clozapine improve cognitive functioning in a sample of 48 patients with chronic schizophrenia who had either failed to show sufficient clinical improvements or suffered from distressing side effects with conventional antipsychotics and were switched to either olanzapine or clozapine for clinical reasons and, if so, whether the two drugs produce similar or different cognitive effects.
METHODS: All patients completed a comprehensive battery of neuropsychological tests designed to index executive functioning, verbal learning, verbal and visual and memory, attention, working memory, and psychomotor speed at: (i) baseline, (ii) after 6 weeks and (iii) after 6 months of treatment with olanzapine or clozapine.
RESULTS: From the initial 48 patients who remained on olanzapine ( n=16) or clozapine ( n=14) for the entire duration with continuous participation, 30 provided data for this study. There were improvements over time (i.e. from baseline through 6 weeks to 6 months) in both treatment groups on verbal fluency, verbal learning and verbal and visual memory measures.
CONCLUSIONS: The findings indicate similar beneficial effects of olanzapine and clozapine on verbal learning and memory measures in patients showing a favourable clinical response to these drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845415     DOI: 10.1007/s00213-003-1506-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

Review 1.  Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects.

Authors:  B Gallhofer; S Lis; A Meyer-Lindenberg; S Krieger
Journal:  Acta Psychiatr Scand Suppl       Date:  1999

2.  A proposed pathological model in the hippocampus of subjects with schizophrenia.

Authors:  E Scarr; D L Copolov; B Dean
Journal:  Clin Exp Pharmacol Physiol       Date:  2001 Jan-Feb       Impact factor: 2.557

3.  Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia.

Authors:  T C Manschreck; D A Redmond; S F Candela; B A Maher
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1999       Impact factor: 2.198

Review 4.  Tardive dyskinesia: prevalence, incidence, and risk factors.

Authors:  J M Kane; M Woerner; J Lieberman
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

5.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

6.  Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Authors:  Robert M Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

7.  Effects of clozapine on awareness of illness and cognition in schizophrenia.

Authors:  S Pallanti; L Quercioli; A Pazzagli
Journal:  Psychiatry Res       Date:  1999-06-30       Impact factor: 3.222

Review 8.  Effects of clozapine on cognitive function in schizophrenia.

Authors:  M A Lee; P A Thompson; H Y Meltzer
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

Review 9.  A review of longitudinal studies of cognitive functions in schizophrenia patients.

Authors:  B R Rund
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 10.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more
  12 in total

1.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

Review 2.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

3.  Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition.

Authors:  J Daniel Ragland; Ruben C Gur; Jeffrey N Valdez; James Loughead; Mark Elliott; Christian Kohler; Stephen Kanes; Steven J Siegel; Stephen T Moelter; Raquel E Gur
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 5.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

7.  Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis.

Authors:  Urs Meyer; Irene Knuesel; Myriel Nyffeler; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2009-12-30       Impact factor: 4.530

8.  Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia.

Authors:  Koichiro Fujimaki; Terumichi Takahashi; Shigeru Morinobu
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

9.  The effect of repetitive transcranial magnetic stimulation on gamma oscillatory activity in schizophrenia.

Authors:  Mera S Barr; Faranak Farzan; Tamara Arenovich; Robert Chen; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

10.  Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial.

Authors:  Ganesh R Pawar; P Phadnis; A Paliwal
Journal:  ISRN Psychiatry       Date:  2012-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.